Create issue ticket

19 Possible Causes for Anti CD22, BL22, Immunotoxin, Recombinant

Show results in: 日本語

  • Hairy Cell Leukemia

    The authors conducted a literature review of the MEDLINE database for articles in English concerning immunotoxins, BRAF inhibitors and BCR pathway inhibitors via PubMed.[] However, complete remission may be achieved with rituximab and the anti-CD22 immunotoxin, BL22.[] Recombinant immunotoxins tested in HCL patients include LMB-2, targeting CD25, and BL22, targeting CD22.[] Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia . N Engl J Med. 2001;345:241-247.[]

  • Acute Lymphoblastic Leukemia

    […] inhibitors in high-risk patient subsets in whom potentially targetable alterations have been identified and (2) immunotherapeutic approaches, such as monoclonal antibodies, immunotoxins[] Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma: a Phase I/II Clinical Trial Results.[] […] from patient samples, BL22 was also found to be highly active in phase 1/2 human studies in hairy cell leukemia. 54 Wayne et al evaluated BL22 in a phase 1 study in childhood[] BCT-100, a pegylated (PEG) recombinant human arginase, can deplete arginine and starve malignant cells of the amino acid.[]

  • Childhood Acute Lymphoblastic Leukemia

    Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin.[] NK activity of the blast cells was augmented by their treatment with 1,000 U/ml recombinant IL-2 (rIL-2): the cytotoxicity level as percentage lysis increased to 38.7% from[] Inotuzumab is an anti-CD22 monoclonal antibody that is conjugated to calicheamicin.[] Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling .[]

    Missing: BL22
  • Hairy Cell Leukemia Variant

    However, preliminary observations suggest that monoclonal antibodies - rituximab and BL-22 immunotoxin are highly active in this disorder even refractory to 2-CdA.[] Promising results have also been obtained with anti-CD22 immunotoxin, BL22.[] Newer therapies may include treatment with a recombinant immunotoxin with an anti-CD22 variable domain fused to a truncated Pseudomonas endotoxin, moxetumomab pasudotox [[] However, complete responses were observed in patients treated with rituximab and anti-CD22 immunotoxins.[]

  • Prolymphocytic Leukemia

    For HCL, your treatment plan may include rituximab and/or BL22 immunotoxin (see Targeted therapy, above).[] Electrophoretic mobility-shift assays revealed that recombinant IL-2 increased NF-kappaB binding activity in nuclear extracts of the leukemia cells, and Northern blot analysis[] […] due to mutation of the ATM gene. 45 The concept of perturbed V(D)J recombination has recently also been shown to be responsible for common deletions of the Ikaros gene in[] Both rituximab and BL22 have been used to treat HCL that did not go into remission after the initial treatment. However, BL22 is not approved by the U.S.[]

    Missing: Anti CD22
  • Cladribine

    HCL-specific trials are listed on a phase II trial of cladribine followed 4 weeks later by 8 weekly doses of rituximab, and phase I-II trials of recombinant immunotoxins[] It also appears to have a lower rate of common adverse events, especially mild to moderate infections [10] [35] As cladribine is not a recombinant biological therapy, it is[] Important Safety Information Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other[] […] listed on a phase II trial of cladribine followed 4 weeks later by 8 weekly doses of rituximab, and phase I-II trials of recombinant immunotoxins targeting CD22 (BL22[]

    Missing: Anti CD22
  • Capillary Leak Syndrome

    A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.[] Article date: September 2013 Background Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are recombinant granulocyte colony-stimulating factors (G-CSF) used to stimulate[] Three- to six-year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor Bone Marrow Transplant 2000 25 : 85–89 Download references[] A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-24. 7.[]

    Missing: BL22
  • T-cell Acute Lymphoblastic Leukemia

    These recombinant immunotoxins were expressed in Escherichia coli and showed that nanobody immunotoxins have the benefits of easy soluble expression in a prokaryotic expression[] Cytoplasmic CD22 1 CD19 CD2 CD117 CD20 CD5 CD13 CD10 CD8 CD33 CD10 CD65 0.5 TdT TdT CD14 CD24 CD7 CD15 CD1a CD64 A score of 2.5 is considered sufficient to assign a lineage[] MeSH terms, Substances MeSH terms Cell Line, Tumor Gene Expression Regulation, Leukemic Humans Immunoglobulin J Recombination Signal Sequence-Binding Protein/biosynthesis[] By metaphase fluorescence in situ hybridization analysis, the AML1 breakpoint was mapped using recombinant phage clones, and shown to be either immediately upstream or downstream[]

    Missing: BL22
  • T-Cell Lymphoblastic Lymphoma

    Immunotoxins can bind to cancer cells and kill them. Denileukin diftitox is an immunotoxin used to treat cutaneous T-cell lymphoma.[] "At the recent American Society of Hematology annual meeting, I presented results of an early-phase study of inotuzumab ozogamicin — a humanized anti-CD22 antibody conjugated[] The observed VH gene replacement events appear to have been mediated by a heptamer sequence homologous to the heptamer of the recombination signal sequence (RSS) located internally[] Cytoplasmic CD22 1 CD19 CD2 CD117 CD20 CD5 CD13 CD10 CD8 CD33 CD10 CD65 0.5 TdT TdT CD14 CD24 CD7 CD15 CD1a CD64 A score of 2.5 is considered sufficient to assign a lineage[]

    Missing: BL22
  • Leprostatic Agent

    These improvements include the use of novel radioisotopes, cytokines, new linkers for chemotherapeutic drugs, more potent drugs, and improved immunotoxins.[] Immunotherapy; CAR-T Cell Immunotherapy; Cellular Immunotherapy, Autologous; Chimeric Antigen Receptor T-Cell Immunotherapy Inotuzumab Ozogamicin Besponsa Antineoplastic Agent, Anti-CD22[] Letermovir Prevymis Antiviral Agent Latanoprostene Bunod Vyzulta Ophthalmic Agent, Antiglaucoma; Prostaglandin, Ophthalmic October 2017 Zoster Vaccine (Recombinant) Shingrix[] Inhibitor Copanlisib Aliqopa PI3 Kinase Inhibitor August 2017 Benznidazole --- Antiprotozoal, Nitroimidazole; Antitrypanosomal Tisagenlecleucel Kymriah Antineoplastic Agent, Anti-CD19[]

    Missing: BL22